Table 2.

Active clinical trials with tagraxofusp (SL401)

Active trial titles	Area of study	Clinicaltrials.gov identifier
SL-401 in combination with pomalidomide and dexamethasone in R/R MM	MM	NCT02661022
SL-401 in combination with AZA or AZA/VEN in AML or high-risk MDS	MDS, AML	NCT03113643
Tagraxofusp (SL-401) in patients with CMML or MF	MF, CMML	NCT02268253
SL-401, venetoclax, and HCVAD chemotherapy for the treatment of BPDCN	BPDCN	NCT04216524
Tagraxofusp in treating patients with BPDCN after SCT	BPDCN	NCT04317781

Source: Clinicaltrials.gov (accessed May 2020).

AZA, azacitidine; MF, myelofibrosis; VEN, venetoclax.